摘要
目的:临床观察和评估干扰素α1b雾化吸入治疗儿童上呼吸道病毒性感染的临床疗效及安全性。方法:采用随机、开放、平行对照方法,163例临床诊断为病毒性上呼吸道感染患儿,分为实验组83例,对照组80例,两组病例治疗前性别、年龄、身高、临床症状等差异无显著性;试验组干扰素α1b雾化吸入治疗,每次生理盐水20mL加干扰素α1b 20万单位,一日两次,对照组生理盐水20mL雾化吸入,每日两次。结果:实验组在退热、感冒症状改善方面与对照组比较,病程缩短,差异有显著性。结论:干扰素α1b雾化吸入疗效确切,药物直达口咽,起效迅速,不良反应小,可作为早期干预上呼吸道病毒感染的首选用药。
Objective: To evaluate the efficacy and safety of nebulized IFN-otlb on viral infection of upper respiratory tract in children. Method: A randomized, open lable, parallel, controlled trial was per-formed. 163 children with viral upper respiratory tract infection were randomly allocated to experiment group (n = 83 ) and control group (n=80). There were no αlt/erenees on genaer, age, height, festation of patients between two groups. Experiment group used interferon-1 alpha, control group used NS. Result: Experiment group compared with control group, There were fine effect in the aspects of pyretolysis and cold improving. There's significant difference between two groups. Conclusion: Interferon-lalpha could be effectively and safety for respiratory virus infection of upper respiratory tract in children, and could easily reach oropharynx in high concentration and fewer adverse effects. A conception of treating common cold using interferon-lalpha aerosol without injection as a first choice are proposed.
出处
《河北医学》
CAS
2012年第8期1045-1048,共4页
Hebei Medicine
关键词
上呼吸道感染
干扰素
病毒
小儿
Upper respiratory tract infection
Interferon-alpha
Virus
Children